The global Tissue Plasminogen Activator Market Growth Accelerated by Increased Demand for Minimally Invasive Treatments
![]() |
Tissue Plasminogen Activator Market |
Tissue
plasminogen activator is a clot-busting drug used in the treatment of stroke.
It helps dissolve dangerous clots and restore blood flow. Tissue plasminogen
activator has the advantage of being highly effective when administered shortly
after the onset of stroke symptoms. Its targeted action minimizes systemic
bleeding risk compared to alternative thrombolytic agents. The surging cases of
strokes worldwide have boosted the demand for clot-dissolving drugs like tissue
plasminogen activator.
The global Tissue Plasminogen Activator Market is estimated to be valued at US$
2.58 Bn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast
period 2023 to 2030, as highlighted in a new report published by Coherent
Market Insights.
Market key trends:
The growing preference for minimally invasive interventions for the treatment
of strokes and blood clots is a major trend driving the tissue plasminogen
activator market. The needle-free and catheter-based administration of tissue
plasminogen activatordissolves dangerous clots through small holes, minimizing
surgical trauma compared to conventional surgeries. This has significantly
increased the adoption of tissue plasminogen activator among healthcare
professionals and patients worldwide. The availability of innovative drug
delivery modes like pre-filled syringes has further simplified the
administration process and ease of use of tissue plasminogen activator, fueling
market revenues.
Segment Analysis
The global tissue plasminogen activator market is segmented on the basis of
type, application and end user. Based on type, the market is segmented into
alteplase, retoplase and tenecteplase. Among these, the alteplase segment
dominates the market due to its higher efficacy in treating acute ischemic
strokes compared to other variants. Based on application, the market is
classified into coronary thrombolysis, pulmonary thrombolysis, and ischemic
stroke. The ischemic stroke segment dominated the market in 2023 due to high
prevalence of strokes worldwide. Based on end user, the market is divided into
hospitals & clinics and ambulatory surgical centers. The hospitals &
clinics segment accounted for the largest share of the market in 2023 due to
availability of advanced infrastructure for emergency treatment of strokes and
availability of skilled healthcare professionals.
Key Takeaways
The Global
Tissue Plasminogen Activator Market Demand is expected to witness high
growth over the forecast period of 2023 to 2030. The global Tissue Plasminogen
Activator Market is estimated to be valued at US$ 2.58 Bn in 2023 and is
expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030.
Regional analysis: North America dominated the global tissue plasminogen
activator market in 2023 owing to increasing prevalence of strokes and strong
healthcare infrastructure in the region for emergency treatment. Asia Pacific
is expected grow at the fastest rate during the forecast period supported by
improving healthcare facilities, increasing disposable incomes and growth in
medical tourism in countries such as India, China and Japan.
Key players: Key players operating in the tissue plasminogen activator market
are Siemens Healthineers AG, GE Healthcare, Koninklijke Philips N.V., Canon
Medical Systems Corporation, Shimadzu Corporation, Hitachi, Ltd., Carestream
Health, Inc., Medtronic plc, Stryker Corporation, Terumo Corporation, Boston
Scientific Corporation, AngioDynamics, Inc., Penumbra, Inc., MicroPort
Scientific Corporation, and Cook Medical LLC. Stryker Corporation is a leader
in the market owing to its diverse product portfolio for minimally invasive
neurovascular procedures.
Get more insights on this topic: https://www.insightprobing.com/tissue-plasminogen-activator-market-growth-market-size-share-analysis/
Comments
Post a Comment